Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation

To evaluate the clinical effect of platelet concentrate (PC) transfusions after PC storage time reduction to 4 days.

[1]  A. Ho,et al.  Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study , 2012, The Lancet.

[2]  S. Assmann,et al.  The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. , 2012, Blood.

[3]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[4]  S. Stanworth,et al.  Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges , 2011, Transfusion.

[5]  M. Schmidt,et al.  Extension of platelet shelf life from 4 to 5 days by implementation of a new screening strategy in Germany , 2011, Vox sanguinis.

[6]  K. Hanschmann,et al.  Transfusion-Transmitted Bacterial Infections – Haemovigilance Data of German Blood Establishments (1997–2010) , 2011, Transfusion Medicine and Hemotherapy.

[7]  D. de Korte.  10 Years Experience with Bacterial Screening of Platelet Concentrates in the Netherlands , 2011, Transfusion Medicine and Hemotherapy.

[8]  L. Corash.  The hemostatic efficacy of platelet components prepared with pathogen inactivation , 2011, Transfusion.

[9]  P. Volkers,et al.  Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures , 2011, Vox sanguinis.

[10]  H. Kirchner,et al.  Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients , 2011, Annals of Hematology.

[11]  E. Seifried,et al.  [Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study]. , 2011, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[12]  E. Seifried,et al.  Konventionelle vs. pathogeninaktivierte Thrombozytenkonzentrate bei perioperativer Koagulopathie , 2011, Der Chirurg.

[13]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[14]  C. Hillyer,et al.  Effects of storage duration and volume on the quality of leukoreduced apheresis‐derived platelets: implications for pediatric transfusion medicine , 2010, Transfusion.

[15]  W. van Putten,et al.  Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction , 2010, British journal of haematology.

[16]  Øystein Bruserud,et al.  Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods , 2010, Transfusion.

[17]  Jeffrey McCullough,et al.  Dose of prophylactic platelet transfusions and prevention of hemorrhage. , 2010, The New England journal of medicine.

[18]  R. Goodrich,et al.  Pathogen reduction technology (Mirasol®) treated single‐donor platelets resuspended in a mixture of autologous plasma and PAS , 2009, Vox sanguinis.

[19]  T. Hervig,et al.  A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. , 2009, Blood.

[20]  N. Heddle,et al.  Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review , 2008, Transfusion.

[21]  Sandra Weiss,et al.  Buffy‐coat platelet variables and metabolism during storage in additive solutions or plasma , 2008, Transfusion.

[22]  A. Gratwohl,et al.  Patient and product factors affecting platelet transfusion results , 2008, Transfusion.

[23]  E. Gündüz,et al.  Platelet function testing during 5-day storage of single and random donor plateletpheresis. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[24]  T. Holland-Letz,et al.  Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood–derived platelets and apheresis platelets , 2007, Transfusion.

[25]  R. Brand,et al.  A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. , 2006, Blood.

[26]  J. Ringwald,et al.  The New Generation of Platelet Additive Solution for Storage at 22°C: Development and Current Experience , 2006 .

[27]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[28]  J. Fridey,et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. , 2004, Blood.

[29]  H. Klüter,et al.  Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets , 2004, Vox sanguinis.

[30]  P. Huijgens,et al.  In vivo PLT increments after transfusions of WBC‐reduced PLT concentrates stored for up to 7 days , 2004, Transfusion.

[31]  J. Seghatchian,et al.  Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[32]  K. Thorpe,et al.  A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets , 2002, Transfusion.

[33]  B. Kocazeybek,et al.  Prospective evaluation of platelets prepared by single and random methods during 5 days of storage: aspects related to quality and quantity. , 2002, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[34]  C. Högman.  Storage of blood components. , 1999, Current opinion in hematology.

[35]  A. Prentice,et al.  A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions , 1997, Transfusion medicine.

[36]  H. Kirchner,et al.  In-vivo evaluation of random donor platelet concentrates from pooled buffy coats , 1996, Annals of Hematology.

[37]  J. Bring,et al.  Evaluation of Platelet Function Using the in vitro Bleeding Time and Corrected Count Increment of Transfused Platelets: Comparison between Platelet Concentrates Derived from Pooled Buffy Coates and Apheresis , 1996, Vox sanguinis.

[38]  J. AuBuchon,et al.  Effect of storage time on clinical efficacy of single‐donor platelet units , 1993, Transfusion.

[39]  U. Bucher,et al.  Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates , 1987, Blut.

[40]  C. Schiffer,et al.  Platelet storage for 7 days in second‐generation blood bags , 1986, Transfusion.

[41]  D. Korte.  10 Years Experience with Bacterial Screening of Platelet Concentrates in the Netherlands , 2011 .

[42]  J. Ringwald,et al.  The new generation of platelet additive solution for storage at 22 degrees C: development and current experience. , 2006, Transfusion medicine reviews.

[43]  C. Schiffer,et al.  Clinical evaluation of platelet concentrates stored for one to five days. , 1986, Blood.